Manchester University NHS Foundation Trust

The NIHR is investing £72 million to establish 14 new Commercial Research Delivery Centres (CRDCs) in England to enhance commercial clinical research speed and efficiency. These centres will support UK's status as a top research location, decentralize clinical trials to community settings, and ensure research inclusion for all eligible communities. Funded by the VPAG Investment Programme and NIHR, the initiative aims to boost UK's life sciences sector and economic growth.

£100 million public-private investment to set up 20 research hubs across the UK, enhancing access to cutting-edge treatments and clinical trials in community settings, boosting economic growth and research delivery leadership in various medical conditions.

Scientists spark optimism for lupus treatment with a new drug trial in the UK, aiming to 'correct' the immune system. Lupus, affecting 69,000 in the UK, primarily women, causes the immune system to attack healthy tissue, potentially damaging vital organs. Symptoms vary widely and include joint pain, rashes, and extreme fatigue. Current treatments suppress the immune system but are not fully effective for all patients.

UCLH initiates CAR T-cell therapy clinical trial for severe lupus patients, aiming to reduce or eliminate life-long medication. The Phase 1 study, CARLYSE, is the first in the UK to test CAR-T therapy for non-cancer diseases, led by UCLH, UCL, and Autolus. Lupus, affecting 69,000 in the UK, lacks a cure and causes organ damage; current treatments have side effects. The trial, involving 12 patients globally, builds on UCL and UCLH's 25-year research on B cell killing in autoimmune diseases, hoping to replicate CAR-T's success in cancer. Participant Katie Tinkler, a lupus patient, expresses hope for a life-changing treatment.

A woman in Manchester is the first UK recipient of CAR-T therapy for severe lupus, aiming to reduce or eliminate life-long medication. The CARLYSE study, led by UCLH and UCL, is the first in the UK to assess CAR-T therapy for non-cancer diseases. Lupus, affecting around 69,000 in the UK, has no cure and current treatments have side effects. The trial, involving multiple specialities, offers hope for a potential cure and improved quality of life for lupus patients.

CAR T-cell therapy, traditionally used in cancer, is being trialed in the UK for severe lupus, potentially offering a cure and eliminating the need for lifelong medication. Early results show promising remission in patients, with some no longer needing lupus drugs.

Three UK lupus patients receive groundbreaking CAR T-cell therapy, potentially eliminating lifelong medication. Early results suggest this one-time treatment could revolutionise lupus treatment, with patients in Germany already in remission. The trial, led by UCLH and UCL, aims to follow patients for 15 years, with hopes of a potential cure for severe lupus.